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Research Round Up- COVID-19, Coagulopathy and Clotting Abnormalities 
Introduction 
The last research round up provided you with an overview of recent research end of life care in a 
global pandemic. In the last 9 months since the start of rapid publications around COVID-19 that I 
feared I may struggle to define a relevant topic for this months round up.  However, as I was reading 
the information around coagulopathy in COVID-19 from a personal perspective it seemed 
appropriate to carry this further for the journal piece. There is emerging evidence that changes to 
coagulation and embolic event are linked with the more serious cases of COVID-19 and may be 
prognostic of outcome as these events contribute to morbidity and mortality. This month I am 
looking at 3 publications around the subject including one that explains the coagulation process to 
help contextualise the problem. There is little related to prescribing choices as initially low molecular 
weight heparin was used but now other anticoagulant medications are being trialled and hopefully 
results form these will be available in the near future.  
 
Coagulopathy and COVID-19 
This review article from Tokyo in Japan was published in March 2020 and outlined what was being 
seen by clinicians dealing with ill patients in the first wave of the COVID-19 pandemic. It was 
recognised fairly early on that many of the patients who were hospitalised with COVID-19 were also 
presenting with coagulopathy issues. This paper also outlines the coagulation process to highlight 
what the changes were doing to the normal clotting cascade mechanisms and how that made be 
used to understand what was compromised. The authors report that the most seriously ill patients 
with coronavirus exhibited clinical signs of varying thrombo-embolic conditions, including 
disseminated intravascular coagulation (DIC) like symptoms, pulmonary embolism and large 
intravascular embolism. They report that bleeding tendency and haemorrhage are rare but that end 
organ function is often affected. These changes can be seen clinically but also in altered blood and 
biochemical biomarkers. They are able to speculatively relate these biomarker changes to altered 
clotting cascade and end outcome events. There is a good discussion on coagulation therapy around 
both the need for it and choice of low molecular weight heparin as an initial intervention. This paper 
helps sets the scene as one of the earliest published discussion of hypercoagulopathy and COVID-19.  
 
Iba, T., Levy, J.H., Levi, M & Thachil, J. (2020) Coagulopathy and COVID-19, J Thromb Heamost 
18:2103-2109 retrieved from  https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14975  
 
COVID‐19 coagulopathy: An in‐depth analysis of the coagulation system 
This original research paper was published in August 2020 reports on a study of 206 Spanish patients 
who presented with COVID-19.  The aim of the study was to analyse the normal bloods taken and 
the coagulation parameters of patients with COVID‐19, This was to determine whether coagulation 
factor derogation occurs and identify potential prognostic biomarkers of the disease. This was a 
retrospective study examining already collected data on patients hospitalised with COVID-19 
between April 3rd and May 3rd 2020.  Participant inclusion was determined by the following criteria; 
being a patient diagnosed  with COVID‐19, over18 years and, hospitalized . Anyone receiving Vitamin 
K therapy was excluded. COVID‐19 diagnosis was defined by ‘positive PCR in nasopharyngeal swab’ 
or by ‘radiologic and analytical findings highly suggestive of the disease’. The bloods that were taken 
were done according to the COVID‐19 protocol in place in that hospital at the time of the study. 
These included red and white cell blood count, biochemistry, C‐reactive protein, procalcitonin, 
ferritin, and interleukin 6. In addition, D-dimer and coagulation factors were also analysed. Of the 
206 participants, 18 died with 188 survivors. The main finding of the study was an elevated d-dimer 
with 69.4% of the patients’ above normal range. Factor VII levels also showed an increasing trend 
but did not reach statistical significance. They conclude that abnormal coagulation and other routine 
laboratory parameters were associated with poor prognosis. Notably, D‐dimer levels were 
significantly higher in non‐survivors who also showed changes to prothrombin.   
 
Martin-Rojas, R.M. etal (2020) COVID‐19 coagulopathy: An in‐depth analysis of the coagulation 




Endothelial Cells Orchestrate COVID-19 Coagulopathy 
This comment piece in the Lancet Haematology section links endothelial cells to covid-19 associated 
coagulopathy. They report that in COVID-19 patients that coagulation activation is widely seen and 
that post mortem reports have identified many cases of widespread microthrombi disseminated 
throughout the pulmonary vasculature, suggesting that vasculopathy is important in COVID-19 
pathogenesis. These post-mortem studies also show substantial endothelial cell damage, with 
evidence of apoptosis (cell death) and loss of tight junctions. Collectively, these data suggest that 
endothelial cells play a key role in orchestrating the unusual pulmonary intravascular coagulopathy 
associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There is a 
good discussion and visual interpretation of the potential activation cascade from endothelium to 
aid understanding. There is a good discussion around the significance of elevated Von Willebrand 
Factor (VWF) and disease severity with more patients who display this symptom being admitted to 
intensive care settings. VWF can bind to platelet receptors causing platelet adhesion and 
aggregation leading to hypercoagulability. Normal blood vessels are lined by an endothelial cell 
monolayer that plays a crucial role in preventing formation of pathological thrombosis. 
Thrombomodulin on endothelial cells has anticoagulant properties. If thrombomodulin is shed, 
which it can be due to cytokine activation, then this anticoagulant property of endothelial cells is 
compromised.  They conclude that further studies will be required to define the different 
mechanisms through which SARS-CoV-2 infection causes such marked endothelial cell effects and 
how this can be ameliorated or managed pharmacologically.  
O’Sullivan, J.M., McGonagle, D., Ward, S.E., Preston, R.J.S. & O’Donnell, J.S. 2020 Endothelial Cells 






There seems to be a growing body of evidence to support potentially significant numbers of patients 
who contract COVID-19 having some vascular and coagulopathy symptoms which may or may not 
cause morbidity and mortality. These range from simple elevated d-dimer with no clinical correlation 
to patients experiencing fatal embolic events. What is evident is that this is an area for significant 
further research and coagulopathy should be assessed for in all patients presenting with 
symptomatic COVID-19 and appropriate anticoagulation therapy prescribed to prevent significant 
embolic events.  
